Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Aging
Interventions: MitoQ, Placebo; Dietary Supplement
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 60 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Bipolar Disorder
Interventions: Lithium / Fluoxetine, Lithium / Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Acute Lung Inflammation
Interventions: Saline, Endotoxin; Other · Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism, Autism Spectrum Disorder, ASD
Interventions: Vasopressin (USP) Injectable Solution [Vasostrict], Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dengue Fever
Interventions: TAK-003, Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more

Conditions: Dry Eye Disease
Interventions: TL-925, Placebo; Drug · Other
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Glendale, California • La Mesa, California + 15 more

Conditions: Fetal Alcohol Spectrum Disorders
Interventions: Choline bitartrate, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 2 Years to 5 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Insomnia
Interventions: Neu-P11; Drug
Lead sponsor: Neurim Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: San Diego, California • Hallandale, Florida • South Miami, Florida + 6 more

Conditions: PANS, PANDAS, Obsessive Compulsive Disorder (OCD)
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 14 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: 2-hydroxybenzylamine acetate, Placebo; Drug · Other
Lead sponsor: MTI Biotech Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stroke
Interventions: Ranitidine, Placebo, Advanced notification, No advanced notification; Drug · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Dermatitis, Atopic
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Healthy Participants
Interventions: REGN10933 + REGN10987, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Day and older
Enrollment: 3,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 132
States / cities: Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more

Conditions: Chronic Pain
Interventions: Oxymorphone Extended Release; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 33
States / cities: Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more

Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions: Tofersen, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more

Conditions: Arthritis, Psoriatic
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Glendale, Arizona • Mesa, Arizona • Jonesboro, Arkansas + 22 more

Conditions: Uveitis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Hypertension
Interventions: Vitamin D (cholecalciferol), Tekturna(Aliskiren) plus placebo; Dietary Supplement · Drug
Lead sponsor: Wayne State University; Other
Eligibility: 30 Years to 74 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Anesthesia, Urethral Obstruction
Interventions: Placebo, Gabapentin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Young Men
Interventions: 600 mg grape seed extract, 600 mg Starch; Dietary Supplement
Lead sponsor: California Baptist University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: Lichen Planopilaris
Interventions: Oral Brepocitinib, Placebo; Drug
Lead sponsor: Priovant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: warfarin, placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 35 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more

Conditions: Hyponatremia
Interventions: Tolvaptan, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: Hawthorne, California • Vista, California • Colorado Springs, Colorado + 9 more

Search by objective public record fields.

Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans

Prevention of Relapse & Recurrence of Bipolar Depression

Effects of Bronchial Segmental Endotoxin Instillation in Humans

Intranasal Vasopressin Treatment in Children With Autism

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting

A Study of LY3471851 in Participants With Eczema

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension

Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion

Effect of Acute Grape Seed Extract Supplementation on the Heart Rate Recovery in Young Individuals

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients